I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19)

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice